GlassScriptPhysician profile
Christopher K Cheng
NPI 1700175312
$2,742.78
in general payments reported to CMS, 2019-2025
33 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $78.19 · 2021: $300 · 2022: $445 · 2023: $1,046 · 2024: $78.87 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.11 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $539.92 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Jazz Pharmaceuticals INC. | $390.54 | 2019-2025 | Xywav |
| Livanova USA, INC. | $177.30 | 2019-2021 | |
| Harmony Biosciences LLC | $170.19 | 2022-2023 | Wakix |
| Ucb, INC. | $163.65 | 2020-2023 | Briviact, Fintepla |
| Supernus Pharmaceuticals, INC. | $157.77 | 2019-2020 | |
| Stryker Corporation | $113.83 | 2025 | Aequalis Perform |
| Itamar Medical INC | $108.00 | 2023 | Watchpatone |
| Teva Pharmaceuticals USA, INC. | $100.28 | 2020-2023 | Austedo Xr |
| Sumitomo Pharma America, INC. | $98.37 | 2023 | Aptiom |
| Lilly USA, LLC | $92.32 | 2019-2023 | Emgality, Reyvow |
| Idorsia Pharmaceuticals US INC | $61.66 | 2023-2024 | Quviviq |
| Medtronic Vascular, INC. | $51.63 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $46.30 | 2023-2024 | Lumryz |
| Csl Behring | $44.65 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $40.19 | 2021-2023 | Vumerity |
| Pfizer INC. | $35.11 | 2023 | |
| Axogen | $30.12 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $29.96 | 2023 | Rexulti |
| Alnylam Pharmaceuticals INC. | $29.74 | 2021 | |
| Inspire Medical Systems, INC. | $29.64 | 2023 | Inspire |
| Alexion Pharmaceuticals, INC. | $28.32 | 2023 | Soliris |
| Biohaven Pharmaceuticals, INC. | $27.87 | 2021 | |
| Amneal Pharmaceuticals LLC | $24.05 | 2023 | Rytary |
| Takeda Pharmaceuticals U.S.A., INC. | $23.74 | 2023 | |
| Greenwich Biosciences, INC. | $23.67 | 2021 | |
| Valeritas, INC. | $19.89 | 2019 | |
| Aquestive Therapeutics, INC. | $17.18 | 2022 | |
| Resmed Corp | $15.77 | 2021 | |
| Ibsa Pharma INC. | $13.77 | 2022 | |
| Tanabe Pharma America, INC. | $13.08 | 2019 | |
| Azurity Pharmaceuticals, INC. | $12.76 | 2023 | Horizant |
| Amgen INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.